RecruitingNCT07197736

Deep Learning for Echo Analysis, Tracking, and Evaluation Prospective Evaluation (DELINEATE-Prospective)

Sponsor: Columbia University

Trial Details

Condition	Valve Disease, Aortic, Mitral Regurgitation (MR), Aortic Stenosis, Valvular Heart Disease, Tricuspid Regurgitation (TR), Aortic Regurgitation
Status	Recruiting
Participants	50
Est. Completion	1 Oct 2027
Last Updated	16 Apr 2026

Primary Outcome

Proportion of Clinically Meaningful Reclassification by Panel Review

Eligibility Criteria

Inclusion Criteria

Inclusion Criteria: * Attending cardiologist employed by Columbia University, ColumbiaDoctors, or NewYork Presbyterian Hospital who reads transthoracic echocardiograms in the Columbia echocardiography laboratory * Provided informed consent to take part in the questionnaires or pivotal study Exclusion Criteria: * Physician in training (cardiology fellow or advanced imaging fellow)

Trial Sites

Countries

United States

View Registry Entry

Related Analysis

DELINEATE-Prospective Trial: AI-Assisted Echocardiography Analysis for Valvular Heart Disease — Real-World Clinical Impact Study

The DELINEATE-Prospective trial evaluates real-time AI assistance for echocardiographic interpretation of valvular heart disease. This Columbia University study tests whether artificial intelligence can improve diagnostic accuracy and reduce inter-observer variability in routine cardiology practice.

Read full article →

This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service